Morgan Stanley Downgrades Intercept Shares To Underweight, Cuts Target To $80
April 08, 2016 at 09:01 AM EDT
Although Ocaliva in primary biliary cholangitis (PBC) has received the backing of an FDA panel, the panel did not endorse the drug for ...